Skip to content

Correlative Study on the Impact of Vasoactive Drug Exposure Dose on Intestinal Function in Early EN Sepsis Patients

Correlative Study on the Impact of Vasoactive Drug Exposure Dose on Intestinal Function in Early EN Sepsis Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104448
Enrollment
Unknown
Registered
2025-06-17
Start date
2025-06-30
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

NEE 15ug/min group:None

Sponsors

Zhongda Hospital, Southeast University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged >= 18 years old; 2.Diagnosis of sepsis conforming to Sepsis 3.0 (infection + SOFA score >= 2 within 24 hours of ICU admission.; 3.Requirement for vasoactive drugs with a usage duration > 24 hours (norepinephrine, epinephrine, dobutamine, or dopamine.; 4.Initiation of enteral nutrition (EN. within 24 hours; 5.Informed consent obtained

Exclusion criteria

Exclusion criteria: 1.Less than 3 months after gastrointestinal surgery; 2.Intestinal function not recovered after gastrointestinal surgery; 3.Presence of gastrointestinal anatomical abnormalities at this admission (e.g., intestinal perforation, mechanical intestinal obstruction, etc..; 4.Acute gastrointestinal diseases within the past 1 month (e.g., gastrointestinal bleeding.; 5.Presence of chronic gastrointestinal diseases (e.g., uncontrolled intestinal tuberculosis, Crohn's disease, etc..; 6.Pancreatitis; 7.Specific nutritional needs, such as long-term home enteral nutrition; 8.Contraindications for enteral nutrition considered by the physician: 9.Vasoactive drug use duration < 24 hours; 10.Pregnant or lactating women; 11.Adults under legal guardianship; 12.Terminally ill patients or those expected to die within 24 hours

Design outcomes

Primary

MeasureTime frame
Enteral Feeding Intolerance Incidence;

Secondary

MeasureTime frame
28-day mortality rate, In-ICU mortality rate, In-hospital mortality rate;Plasma citrulline concentration on Day 1/Day 3/Day 7, Plasma intestinal fatty acid-binding protein (I-FABP) concentration on Day 1/Day 3/Day 7;Mesenteric vascular resistance on Day 1/Day 3/Day 7;

Countries

China

Contacts

Public ContactMo Min

Zhongda Hospital, Southeast University

momin_2002@163.com+86 139 1471 9904

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026